Literature DB >> 12741725

Molecular mechanisms of fluoroquinolone resistance.

Feng-Jui Chen1, Hsiu-Jung Lo.   

Abstract

Fluoroquinolones have a broad spectrum of activity for complicated urinary tract infections, gastrointestinal infections, respiratory tract infections, sexually transmitted diseases, and chronic osteomyelitis. Since fluoroquinolones are excellent antibiotics for a number of clinical indications, their consumption has increased rapidly, both in human medicine and in food animals. Resistance to fluoroquinolones is chromosomal mediated, involving mutations either in the target genes including DNA gyrase (gyrA or gyrB) and topoisomerase IV (parC or parE), or in the regulatory factors controlling bacterial permeability or the efflux capacity of the bacteria. This review focuses on mechanisms of fluoroquinolone resistance, including known and proposed molecular mechanisms. This review also discuses the clinical impact of fluoroquinolone-resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12741725

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  15 in total

1.  Fluoroquinolone-resistant mutants of Burkholderia cepacia.

Authors:  C F Pope; S H Gillespie; J R Pratten; T D McHugh
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

2.  Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis.

Authors:  I Lysnyansky; I Mikula; I Gerchman; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

3.  Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.

Authors:  Anjali N Kunz; Afrin A Begum; Hong Wu; Jonathan A D'Ambrozio; James M Robinson; William M Shafer; Margaret C Bash; Ann E Jerse
Journal:  J Infect Dis       Date:  2012-04-05       Impact factor: 5.226

4.  Synthesis and antibacterial properties of new 8-nitrofluoroquinolone derivatives.

Authors:  Yusuf M Al-Hiari; Inas Saleh Al-Mazari; Ashok K Shakya; Rula M Darwish; Rana Abu-Dahab
Journal:  Molecules       Date:  2007-06-30       Impact factor: 4.411

5.  A toxicity and hazard assessment of fourteen pharmaceuticals to Xenopus laevis larvae.

Authors:  Sean M Richards; Shaun E Cole
Journal:  Ecotoxicology       Date:  2006-11-01       Impact factor: 2.823

6.  Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa.

Authors:  Nicole Wolter; Mignon du Plessis; Anne von Gottberg; Linda de Gouveia; Keith P Klugman
Journal:  J Clin Microbiol       Date:  2009-03-04       Impact factor: 5.948

7.  A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.

Authors:  Thomas Gruger; John L Nitiss; Anthony Maxwell; E Lynn Zechiedrich; Peter Heisig; Siegfried Seeber; Yves Pommier; Dirk Strumberg
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Prospective study of antibiotic prophylaxis for prostate biopsy involving >1100 men.

Authors:  Rustom P Manecksha; Gregory J Nason; Ivor M Cullen; Jérôme P Fennell; Elizabeth McEvoy; Ted McDermott; Robert J Flynn; Ronald Grainger; John A Thornhill
Journal:  ScientificWorldJournal       Date:  2012-05-02

9.  Rapid assessment of the effect of ciprofloxacin on chromosomal DNA from Escherichia coli using an in situ DNA fragmentation assay.

Authors:  María Tamayo; Rebeca Santiso; Jaime Gosalvez; Germán Bou; José Luis Fernández
Journal:  BMC Microbiol       Date:  2009-04-13       Impact factor: 3.605

10.  Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis.

Authors:  S Khimdas; K L Visscher; C M L Hutnik
Journal:  Ophthalmol Eye Dis       Date:  2011-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.